Therma Bright’s Investment Company InStatin Signs Discovery Study Agreement With Mountain West Research
The clinical research study will provide InStatin with insights for specific targeting of active pharmaceutical ingredients (API) that will further support its Phase 1 Human Trials.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment portfolio company InStatin on its recent agreement with Mountain West Research to conduct a comprehensive non-GLP discovery study.
The pivotal study will explore the pharmacokinetics of the InStatin innovative statin inhalant solution’s active pharmaceutical ingredient (API) in both lung and systemic blood circulation.
This pre-clinical research aims to provide crucial insights to aid InStatin’s team in furthering the development of its advanced therapeutic solution for asthma and chronic obstructive pulmonary disease (COPD). The research will help clarify how to properly target the delivery of the solution’s active pharmaceutical ingredients (API) in the lungs to enhance the efficacy, bioavailability, and overall treatment outcomes.
Commenting on the agreement, Therma Bright CEO Rob Fia, stated:
“The research efforts between InStatin and Mountain West Research underscores our investment portfolio company’s commitment to our vision of ‘Transforming Innovation into Wellness’ with the pursuit of developing effective asthma and COPD treatments. We are confident that the findings from this study will validate the potential of innovative lung delivery systems and their positive impact on patient health.”
InStatin continues to push the boundaries of pharmaceutical research in respiratory solutions, and this study marks an important step toward unlocking new possibilities in treatment methodologies. The results are considered critical in guiding the next phases of InStatin’s product development in preparation for Phase 1 human trials.
Nova1Advisor’s report, as announced in a BioSpace article, projects the Asthma Treatment market size will “hit around USD 39.04 billion by 2032, growing at a CAGR of 3.8% during the forecast period 2023 to 2032.” Therma Bright owns 17% of InStatin with the SAFE investment increasing the Company’s ownership in the future at a discount to the next round of financing secured by InStatin.
Therma Bright (TSXV: THRM) Stock Price Action
Shares of Therma Bright (TSXV: THRM) stock last traded at $0.055.
YTD, THRM stock is up 83.33%.
View Therma Bright Stock Chart on Barchart
Join the Discussion in the WVC Facebook Investor Group
Have a Stock Tip or New Story Suggestion? Email us at Invest@WealthyVC.com
Therma Bright (TSXV: THRM) is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
